➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Medtronic
McKesson
Mallinckrodt
Boehringer Ingelheim

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PRINIVIL

« Back to Dashboard

All Clinical Trials for Prinivil

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00459056 The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients Completed GlaxoSmithKline Phase 3 2007-04-01 The purpose of this study is to compare the effects of two different combination therapies for high blood pressure on vascular health.
NCT00459056 The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients Completed St. Paul Heart Clinic Phase 3 2007-04-01 The purpose of this study is to compare the effects of two different combination therapies for high blood pressure on vascular health.
NCT01669434 Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery Enrolling by invitation University of Nebraska Phase 4 2015-06-01 Primary research hypothesis: Patients who continue their chronic ACEI therapy up to and including the morning of an intermediate risk surgery will experience more intraoperative hypotension than those who hold their chronic ACEI perioperatively. Secondary research hypothesis #1: Patients who continue their chronic ACEI up to and including the morning of an intermediate risk surgery will experience better postoperative control of hypertension than those who hold their chronic ACEI perioperatively. Secondary research hypothesis #2: Patients who continue their chronic ACEI up to and including the morning of an intermediate risk surgery will experience less acute renal failure than those who hold their chronic ACEI perioperatively. Secondary research hypothesis #3: Patients with a preoperative systolic blood pressure less than 110 mmHg who are continued on their chronicACEI therapy perioperatively will have a significant decrease in blood pressure during anesthesia compared to those who have a preoperative systolic blood pressure greater than 110 who are continued on their chronic ACEI. Secondary research hypothesis #4: Patients above the age of 64 who are continued on their chronic ACEI therapy perioperatively will have a significant decrease in blood pressure during anesthesia compared to those aged 64 or younger who are continued on their chronic ACEI.
NCT02623036 The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors Recruiting Memorial Health University Medical Center Phase 1 2015-11-01 The purpose of this study is to use ambulatory blood pressure monitors to investigate whether enalapril is superior to lisinopril in managing nocturnal hypertension in patients with resistant hypertension currently treated with daytime angiotensin converting enzyme inhibitors.
NCT02853045 Comparison of Blood Pressure Control Achieved in Antihypertensive or Generic Drugs in Moderate to Severe Hypertensive Patients Recruiting Centre Hospitalier Universitaire de Saint Etienne Phase 4 2015-06-01 Despite a large diffusion for generic anti-hypertensive, they are not currently used. Clinical validation studies could be better to convince users and prescribers than pharmacologic validation only. A pragmatic study to evaluate generic anti-hypertensive efficacy is proposed. It takes place in real conditions of care for hypertensive patients, for a manometer control criteria. The aim of the study is to test the hypothesis of non-inferiority for generic anti-hypertensive for blood pressure control.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Prinivil

Condition Name

Condition Name for Prinivil
Intervention Trials
Hypertension 4
Abdominal Obesity 1
Osteonecrosis Due to Drug 1
Osteonecrosis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Prinivil
Intervention Trials
Hypertension 2
Cardiomyopathies 1
Liver Diseases 1
Fatty Liver 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Prinivil

Trials by Country

Trials by Country for Prinivil
Location Trials
United States 5
France 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Prinivil
Location Trials
Minnesota 2
Tennessee 1
Georgia 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Prinivil

Clinical Trial Phase

Clinical Trial Phase for Prinivil
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 2 3
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Prinivil
Clinical Trial Phase Trials
Not yet recruiting 3
Recruiting 2
Completed 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Prinivil

Sponsor Name

Sponsor Name for Prinivil
Sponsor Trials
National Cancer Institute (NCI) 2
Memorial Health University Medical Center 1
University of Nebraska 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Prinivil
Sponsor Trials
Other 6
NIH 2
Industry 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Medtronic
Mallinckrodt
Boehringer Ingelheim
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.